<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02119039</url>
  </required_header>
  <id_info>
    <org_study_id>OPHT-070214</org_study_id>
    <nct_id>NCT02119039</nct_id>
  </id_info>
  <brief_title>Effect of CACICOL20 on Corneal Epithelial Healing After Cross-linking in Patients With Keratoconus</brief_title>
  <official_title>Effect of CACICOL20 on Corneal Epithelial Healing After Cross-linking in Patients With Keratoconus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <brief_summary>
    <textblock>
      CACICOL20 is an ophthalmic solution based on the technology of RGTAs (ReGeneraTingAgents). It
      consists of large biopolymers, imitating the structure of heparansulphate. The protecting
      effect on different biological tissues and enhancement of wound healing has been described in
      several studies.

      Keratoconus is a relatively common disease, with incidences ranging from 1.3 to 25 per
      100,000 per year across different populations. Corneal collagen cross-linking represents a
      treatment option for these patients, aiming to prevent progression of the disease via
      stabilization of corneal microstructure. Corneal epithelial removal prior to the ultraviolet
      A/riboflavin cross-linking procedure significantly improves the outcome of the intervention,
      due to ameliorated distribution of riboflavin.

      The aim of the present study is to investigate the effect of CACICOL20 on corneal epithelial
      wound closure after collagen cross-linking in patients with keratoconus. Results may lead to
      an improved management and pain reduction of patients with corneal epithelial defects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to closure of the epithelial wound</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Keratoconus</condition>
  <arm_group>
    <arm_group_label>RGTA OTR 4120 (CACICOL20)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Genteal HA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RGTA OTR 4120 (CACICOL20)</intervention_name>
    <arm_group_label>RGTA OTR 4120 (CACICOL20)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Genteal HA eye drops</intervention_name>
    <arm_group_label>Genteal HA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged over 18 years

          -  Presence of keratoconus

          -  Scheduled for corneal cross linking

          -  No ophthalmic surgery in the 3 months preceding the study

        Exclusion Criteria:

          -  Participation in a clinical trial in the previous 3 weeks

          -  Topical use of aminoglycosid antibiotics

          -  Use of therapeutic or refractive contact lenses after surgery

          -  Known hypersensitivity to any component of the study medication or heparinoids or
             heparin

          -  Active ocular infection

          -  Presence of any abnormalities preventing reliable measurements as judged by the
             investigator

          -  Pregnancy, planned pregnancy or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Clinical Pharmacology, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2014</study_first_submitted>
  <study_first_submitted_qc>April 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2014</study_first_posted>
  <last_update_submitted>December 21, 2015</last_update_submitted>
  <last_update_submitted_qc>December 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Katarzyna J. Witkowska</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Cross-linking</keyword>
  <keyword>RGTA OTR4120 (CACICOL20)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

